Liver Metastases Do Not Predict Resistance to the Addition of Atezolizumab to First-Line FOLFOXIRI Plus Bevacizumab in Proficient MMR Metastatic Colorectal Cancer: a Secondary Analysis of the AtezoTRIBE Study.
ESMO open(2025)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要